Etoricoxib Brown
Generic Selective COX-2 Inhibitor for Arthritis, Gout & Pain
Etoricoxib Brown is a generic prescription medicine containing the active ingredient etoricoxib, a selective cyclo-oxygenase-2 (COX-2) inhibitor belonging to the coxib class of nonsteroidal anti-inflammatory drugs (NSAIDs). It is used to treat pain and inflammation associated with osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute gouty arthritis, and short-term moderate pain after dental surgery in patients aged 16 years and older. This formulation is available as a 30 mg film-coated tablet. Etoricoxib Brown is bioequivalent to the originator product Arcoxia, meaning it delivers the same therapeutic effect. It selectively blocks COX-2 while largely sparing COX-1, which may reduce the risk of gastrointestinal side effects compared to traditional NSAIDs. Etoricoxib Brown requires a prescription and is taken once daily.
Quick Facts
Key Takeaways
- Etoricoxib Brown contains etoricoxib, a selective COX-2 inhibitor that reduces pain, inflammation, and swelling by targeting the COX-2 enzyme while sparing COX-1, potentially reducing gastrointestinal side effects compared to traditional NSAIDs such as ibuprofen or naproxen.
- This formulation is available as a 30 mg film-coated tablet, the lowest approved strength of etoricoxib, primarily indicated for the symptomatic treatment of osteoarthritis. Higher doses for other conditions may require different formulations or brands.
- Etoricoxib has a long half-life of approximately 22 hours, allowing convenient once-daily dosing across all approved indications.
- It is contraindicated in patients with established cardiovascular disease, uncontrolled hypertension, severe liver or kidney disease, inflammatory bowel disease, pregnancy, and breastfeeding.
- The most common side effect is stomach pain; serious but less common risks include cardiovascular events, elevated blood pressure, and liver problems. Use the lowest effective dose for the shortest duration necessary.
What Is Etoricoxib Brown and What Is It Used For?
Etoricoxib Brown belongs to the coxib subclass of nonsteroidal anti-inflammatory drugs (NSAIDs), a group of medicines designed to selectively inhibit cyclo-oxygenase-2 (COX-2). The COX-2 enzyme is primarily responsible for producing prostaglandins at sites of tissue damage and inflammation. By selectively blocking COX-2, etoricoxib reduces prostaglandin synthesis in inflamed tissues, thereby providing effective pain relief, reducing swelling, and lowering fever, while having a significantly lesser effect on COX-1—the enzyme that helps protect the stomach lining and supports normal platelet function.
As a generic medicine, Etoricoxib Brown contains the same active ingredient as the originator product Arcoxia, which was developed by Merck & Co. and first received marketing authorization in 2002. Generic medications must meet stringent bioequivalence standards set by regulatory authorities such as the European Medicines Agency (EMA), demonstrating that they deliver the same amount of active ingredient into the bloodstream at the same rate as the originator product. This means Etoricoxib Brown 30 mg is therapeutically equivalent to Arcoxia 30 mg, offering the same clinical efficacy and safety profile at a typically more affordable price point.
Etoricoxib is approved in over 80 countries worldwide, including throughout Europe, Latin America, and Asia-Pacific. It has not received FDA approval for the United States market; the FDA declined approval in 2007, requesting additional cardiovascular safety data. Nevertheless, etoricoxib remains one of the most widely prescribed selective COX-2 inhibitors globally, with extensive clinical trial data supporting its efficacy and safety profile. The MEDAL (Multinational Etoricoxib and Diclofenac Arthritis Long-term) program, involving over 34,700 patients, demonstrated comparable cardiovascular safety to diclofenac with significantly fewer upper gastrointestinal events.
Approved Indications
Etoricoxib is licensed for the treatment of several chronic and acute inflammatory conditions in patients aged 16 years and older. The 30 mg strength of Etoricoxib Brown is primarily prescribed for osteoarthritis, while other indications may require higher doses available from alternative formulations. The approved indications for etoricoxib include:
- Osteoarthritis – The most common form of arthritis, caused by gradual breakdown of the cartilage that cushions the ends of bones in joints. The recommended starting dose is 30 mg once daily, which may be increased to 60 mg if symptom control is insufficient. Etoricoxib effectively manages the chronic pain, stiffness, swelling, and reduced joint mobility associated with osteoarthritis, and has been shown in clinical trials to be as effective as non-selective NSAIDs such as diclofenac and naproxen for this indication.
- Rheumatoid arthritis – A chronic autoimmune inflammatory disease that affects the joints, causing pain, stiffness, swelling, and progressive loss of function. The recommended dose is 60 mg once daily, which may be increased to 90 mg if necessary. Etoricoxib provides sustained relief of joint symptoms and morning stiffness, complementing disease-modifying antirheumatic drugs (DMARDs) in comprehensive treatment strategies.
- Ankylosing spondylitis – A chronic inflammatory disease primarily affecting the spine and large joints, causing back pain and stiffness. NSAIDs, including etoricoxib, are recommended as first-line pharmacological treatment according to European League Against Rheumatism (EULAR) and Assessment of SpondyloArthritis international Society (ASAS) guidelines. The recommended dose is 60 mg once daily, which may be increased to 90 mg.
- Acute gouty arthritis – Gout is a joint disease characterized by sudden, recurrent attacks of severe pain, inflammation, and redness caused by the deposition of monosodium urate crystals. Etoricoxib 120 mg once daily is effective for relieving the acute pain of gout flares, limited to a maximum of 8 days. Clinical studies have shown it to be as effective as indomethacin with fewer gastrointestinal side effects.
- Moderate pain after dental surgery – Etoricoxib 90 mg once daily is approved for short-term management of moderate pain following dental procedures, limited to a maximum of 3 days, providing an alternative to opioid analgesics.
How Etoricoxib Works
Etoricoxib exerts its therapeutic effects through highly selective inhibition of the COX-2 enzyme. In human whole blood assays, etoricoxib demonstrates a COX-1 to COX-2 selectivity ratio of approximately 106-fold, making it one of the most COX-2 selective agents in clinical use. This high selectivity means that at therapeutic doses, etoricoxib produces potent anti-inflammatory and analgesic effects through COX-2 inhibition while having minimal impact on COX-1-mediated physiological processes such as gastric mucosal protection, platelet aggregation, and renal hemodynamics.
After oral administration, etoricoxib is rapidly and almost completely absorbed, with an oral bioavailability of approximately 100%. Peak plasma concentrations are typically reached within 1 hour, and its elimination half-life of approximately 22 hours supports convenient once-daily dosing across all approved indications. The drug is extensively metabolized in the liver, primarily by CYP3A4 enzymes, and approximately 70% of an oral dose is excreted in the urine as metabolites. Etoricoxib is highly protein-bound (approximately 92%) and has a volume of distribution of approximately 120 liters in humans.
The pharmacokinetic profile of etoricoxib is notably consistent and predictable, which simplifies dosing and clinical management. Food does not significantly affect the overall extent of absorption, although it may slightly delay the time to peak concentration. This means Etoricoxib Brown can be taken with or without food at any convenient time of day, provided it is taken at approximately the same time each day to maintain consistent blood levels.
Generic medicines like Etoricoxib Brown undergo rigorous regulatory review to ensure they meet the same quality, safety, and efficacy standards as the original branded product. The EMA and other international regulatory agencies require generic manufacturers to demonstrate bioequivalence through pharmacokinetic studies, confirming that the generic delivers the active ingredient to the bloodstream at the same rate and extent as the originator. Generic medicines play a vital role in improving access to essential treatments worldwide.
What Should You Know Before Taking Etoricoxib Brown?
Before starting treatment with Etoricoxib Brown, it is essential to carefully review the contraindications and precautions with your doctor. Etoricoxib, like all NSAIDs, carries certain risks that must be weighed against its benefits. Your doctor will consider your complete medical history, current medications, and individual risk factors before prescribing this medicine. The general principle of NSAID prescribing applies: use the lowest effective dose for the shortest duration necessary to control symptoms.
Contraindications
Etoricoxib Brown must not be taken in the following situations. If any of these apply to you, inform your doctor immediately:
- Allergy to etoricoxib or any excipient – If you have previously experienced allergic reactions to etoricoxib or any other ingredient in the tablets, you must not take this medicine. Allergic reactions can range from mild skin rashes to severe anaphylaxis.
- NSAID hypersensitivity – If you have had allergic reactions (including asthma, urticaria, rhinitis, or angioedema) after taking aspirin or any other NSAID, including other COX-2 inhibitors such as celecoxib, you must not take Etoricoxib Brown. Cross-reactivity among NSAIDs can trigger severe and potentially life-threatening reactions.
- Active peptic ulcer or gastrointestinal bleeding – If you currently have a stomach ulcer or bleeding in the stomach or intestines. Active gastrointestinal ulceration or bleeding is an absolute contraindication for all NSAIDs.
- Severe liver disease – Patients with advanced hepatic impairment (Child-Pugh score above 9) must not take etoricoxib, as significantly altered drug metabolism increases the risk of toxicity and hepatic adverse events.
- Severe kidney disease – Patients with estimated creatinine clearance below 30 ml/min must not take etoricoxib. NSAIDs inhibit prostaglandin-mediated renal blood flow regulation, which can precipitate acute renal failure in patients with pre-existing severe renal impairment.
- Inflammatory bowel disease – Active Crohn's disease, ulcerative colitis, or colitis. NSAIDs can exacerbate inflammatory bowel disease and trigger disease flares.
- Uncontrolled hypertension – Blood pressure that has not been adequately controlled with treatment. Etoricoxib can further elevate blood pressure, increasing cardiovascular risk. If you are uncertain whether your blood pressure is under control, check with your doctor before starting treatment.
- Established cardiovascular disease – Including heart failure (moderate or severe, NYHA class II–IV), angina pectoris, history of myocardial infarction, coronary artery bypass graft surgery, peripheral arterial disease, or any form of cerebrovascular disease (stroke or transient ischemic attack). Selective COX-2 inhibitors are associated with an increased risk of thrombotic cardiovascular events in these high-risk patients.
- Pregnancy and breastfeeding – Etoricoxib Brown must not be used during pregnancy or while breastfeeding. NSAIDs can have adverse effects on fetal cardiovascular and renal development, particularly during the third trimester.
- Age under 16 years – Not approved for use in children and adolescents below 16 years of age due to insufficient safety and efficacy data.
Warnings and Precautions
Even when Etoricoxib Brown is not strictly contraindicated, there are many situations in which extra caution is necessary. Speak to your doctor before using etoricoxib if any of the following apply:
Selective COX-2 inhibitors may be associated with a small increased risk of cardiovascular thrombotic events, including myocardial infarction and stroke, particularly when used at high doses for prolonged periods. Use the lowest effective dose for the shortest duration necessary. Etoricoxib Brown must not be used in patients with established cardiovascular disease or uncontrolled hypertension. Patients with cardiovascular risk factors (diabetes, high cholesterol, smoking) should discuss the risk-benefit balance with their doctor.
- History of gastrointestinal problems – Previous stomach or duodenal ulcers, gastrointestinal bleeding, or peptic ulcer disease increase the risk of recurrence. Your doctor may prescribe a gastroprotective agent (such as a proton pump inhibitor) alongside etoricoxib if you have a history of GI complications.
- Concurrent use of other NSAIDs or aspirin – Taking etoricoxib with other NSAIDs or high-dose aspirin increases the risk of gastrointestinal ulceration and bleeding. Low-dose aspirin for cardiovascular prevention may be taken concurrently, but with increased GI monitoring.
- Dehydration – If you are dehydrated (for example, after prolonged vomiting or diarrhea), rehydration is recommended before starting etoricoxib, as dehydration increases the risk of renal adverse effects.
- Fluid retention or edema – Etoricoxib may cause sodium and fluid retention, which can worsen pre-existing edema or heart failure. Patients with a history of fluid retention should be monitored closely.
- History of heart failure or cardiac disease – Even without established cardiovascular disease, discuss your cardiac history with your doctor, as NSAIDs may affect cardiac function.
- Hypertension – Etoricoxib can increase blood pressure in some patients, particularly at higher doses. Your doctor should measure your blood pressure before initiating treatment, within two weeks of starting, and periodically thereafter.
- Liver or kidney disease – Even mild to moderate impairment requires dose adjustment and careful monitoring. For mild liver disease (Child-Pugh score 5–6), do not exceed 60 mg daily. For moderate liver disease (Child-Pugh score 7–9), do not exceed 30 mg daily.
- Infections – Etoricoxib may mask fever and other signs of infection, potentially delaying appropriate diagnosis and treatment of bacterial or viral infections.
- Elderly patients (over 65 years) – No dose adjustment is required, but physicians should monitor treatment more closely due to the increased vulnerability to gastrointestinal, cardiovascular, and renal adverse effects in this population.
Pregnancy and Breastfeeding
Etoricoxib Brown is contraindicated during pregnancy. If you are pregnant, suspect you may be pregnant, or are planning to become pregnant, do not take this medicine. Discontinue Etoricoxib Brown immediately and consult your doctor if you become pregnant during treatment. NSAIDs, including selective COX-2 inhibitors, can have adverse effects on fetal development, particularly on the cardiovascular and renal systems, especially during the third trimester. Specifically, NSAIDs may cause premature closure of the ductus arteriosus, oligohydramnios, and impaired fetal renal function.
It is not known whether etoricoxib passes into human breast milk. If you are breastfeeding or planning to breastfeed, consult your doctor before taking Etoricoxib Brown. If you do take Etoricoxib Brown, you should not breastfeed. Etoricoxib is also not recommended for women who are trying to conceive, as it may impair fertility by affecting ovulation. This effect is reversible upon discontinuation of the medicine.
Driving and Using Machines
Dizziness and drowsiness have been reported by some patients taking etoricoxib. If you experience either of these effects, do not drive, operate machinery, or perform activities requiring alertness until the symptoms resolve. Always assess your own fitness before engaging in such activities when taking any medication. Most patients do not experience these effects, and they are more commonly reported during the initial days of treatment.
How Does Etoricoxib Brown Interact with Other Drugs?
Drug interactions are an important consideration when taking etoricoxib. The metabolism of etoricoxib occurs primarily through CYP3A4 in the liver, and it can affect the pharmacokinetics and pharmacodynamics of several other medications. Conversely, drugs that strongly induce CYP3A4 (such as rifampicin) can significantly reduce etoricoxib plasma concentrations, potentially diminishing its therapeutic effect. Always inform your doctor and pharmacist about all medications you are currently taking, including over-the-counter medicines, vitamins, and herbal supplements.
It is particularly important to recognize that even though Etoricoxib Brown 30 mg is the lowest available strength, drug interactions remain clinically relevant. The 30 mg dose is most commonly used for osteoarthritis, a condition often managed alongside other chronic medications, making awareness of potential interactions essential for safe and effective treatment.
Major Interactions
| Drug / Drug Class | Interaction Effect | Clinical Advice |
|---|---|---|
| Warfarin and other anticoagulants | Etoricoxib may enhance the anticoagulant effect, increasing INR and bleeding risk. | Close INR monitoring when starting, adjusting, or stopping etoricoxib. |
| Lithium | NSAIDs reduce renal lithium clearance, raising plasma levels and toxicity risk. | Monitor lithium plasma levels. Dose adjustment may be necessary. |
| Methotrexate | NSAIDs may reduce renal clearance of methotrexate, increasing toxicity risk. | Monitor for methotrexate-related adverse effects, especially at high doses. |
| Ciclosporin / Tacrolimus | Increased nephrotoxicity risk due to additive renal prostaglandin inhibition. | Monitor renal function closely during concurrent use. |
| ACE inhibitors & ARBs | Reduced antihypertensive effect and increased risk of acute kidney injury. | Monitor blood pressure and renal function. Ensure adequate hydration. |
| Diuretics | Reduced diuretic and antihypertensive effects through sodium retention. | Monitor blood pressure and fluid balance. |
| Digoxin | NSAIDs may increase digoxin plasma levels, raising toxicity risk. | Monitor digoxin levels and watch for signs of toxicity. |
Other Notable Interactions
- Rifampicin – A potent CYP3A4 inducer that can reduce etoricoxib plasma concentrations by approximately 65%, potentially significantly reducing its therapeutic effect. If concurrent use is unavoidable, your doctor may need to consider alternative pain management strategies.
- Oral contraceptives – Etoricoxib 120 mg has been shown to increase ethinylestradiol plasma concentrations by 50–60%, which may increase the risk of thromboembolic events such as deep vein thrombosis and pulmonary embolism. This interaction is dose-dependent and is less pronounced at the 30 mg dose, but should still be considered, especially in women with additional risk factors for thrombosis.
- Hormone replacement therapy (HRT) – Similar to oral contraceptives, the combination may increase the risk of adverse effects from estrogen therapy. Discuss the risk-benefit balance with your doctor.
- Aspirin (low-dose) – Low-dose aspirin for cardiovascular prevention can be taken with etoricoxib, but the combination increases gastrointestinal bleeding risk. Do not take high-dose aspirin or other NSAIDs together with Etoricoxib Brown, as this provides no additional benefit and significantly increases the risk of adverse effects.
- Minoxidil – Etoricoxib may reduce the antihypertensive effect of minoxidil through prostaglandin inhibition and sodium retention.
- Salbutamol (oral) – Etoricoxib may increase plasma concentrations of oral salbutamol formulations. This interaction is not clinically significant with inhaled salbutamol.
Etoricoxib Brown can be taken with or without food. While food may slightly delay absorption, the overall extent of absorption is not affected. This is not clinically significant for any approved indication. Taking the tablet at the same time each day helps maintain consistent blood levels.
What Is the Correct Dosage of Etoricoxib Brown?
Always take Etoricoxib Brown exactly as your doctor has prescribed. It is important to use the lowest possible dose that effectively controls your symptoms, and treatment should not be continued longer than necessary. The risk of cardiovascular events may increase with higher doses and longer duration of use. Your doctor may periodically reassess your treatment to determine whether continued use is appropriate.
Adults
Etoricoxib Brown 30 mg tablets are the lowest available strength. The prescribed dose depends on the specific condition being treated. For indications requiring higher doses (60 mg, 90 mg, or 120 mg), your doctor may prescribe a different etoricoxib formulation or brand that offers the appropriate strength:
| Indication | Recommended Dose | Maximum Dose | Duration |
|---|---|---|---|
| Osteoarthritis | 30 mg once daily | 60 mg once daily | Long-term (as needed) |
| Rheumatoid arthritis | 60 mg once daily | 90 mg once daily | Long-term (as needed) |
| Ankylosing spondylitis | 60 mg once daily | 90 mg once daily | Long-term (as needed) |
| Acute gout | 120 mg once daily | 120 mg once daily | Max 8 days |
| Post-dental surgery pain | 90 mg once daily | 90 mg once daily | Max 3 days |
For osteoarthritis, treatment typically begins with 30 mg once daily using Etoricoxib Brown. If adequate symptom control is not achieved after a reasonable trial period (usually at least two weeks), your doctor may increase the dose to 60 mg once daily. The 30 mg dose provides effective pain relief and functional improvement for many patients with osteoarthritis while minimizing the risk of dose-dependent side effects such as elevated blood pressure and fluid retention.
Children and Adolescents
Etoricoxib Brown is not approved for use in children and adolescents under 16 years of age. There is insufficient clinical data on safety and efficacy in this age group. If a young person aged 16 or older requires treatment, adult dosing recommendations apply under appropriate medical supervision.
Elderly Patients
No dose adjustment is necessary for elderly patients. Etoricoxib is equally effective in older adults as in younger patients. However, as with all NSAIDs, particular caution is warranted in patients over 65 years due to increased vulnerability to gastrointestinal, cardiovascular, and renal adverse effects. Elderly patients are more likely to be taking multiple medications concurrently, increasing the potential for drug interactions. Your doctor may wish to monitor your treatment more closely, including regular blood pressure checks, renal function tests, and assessment of gastrointestinal symptoms.
Patients with Liver Disease
Dose adjustments are required for patients with hepatic impairment:
- Mild liver disease (Child-Pugh score 5–6) – Do not exceed 60 mg daily.
- Moderate liver disease (Child-Pugh score 7–9) – Do not exceed 30 mg daily. Etoricoxib Brown 30 mg is therefore the maximum recommended dose for these patients.
- Severe liver disease (Child-Pugh score above 9) – Etoricoxib is contraindicated.
Patients with Kidney Disease
No dose adjustment is required for patients with creatinine clearance above 30 ml/min. Etoricoxib is contraindicated in patients with severe renal impairment (creatinine clearance below 30 ml/min). For patients with moderate renal impairment, regular monitoring of renal function is recommended during treatment.
Missed Dose
If you forget to take a dose of Etoricoxib Brown, simply resume your regular schedule the following day. Do not take a double dose to compensate for a missed one. Because etoricoxib has a long half-life of approximately 22 hours, missing a single dose may still provide some residual effect. However, consistent daily dosing provides the most reliable symptom control.
Overdose
Never take more tablets than your doctor has prescribed. If you or someone else has taken more than the recommended dose of Etoricoxib Brown, contact your local poison control center or seek emergency medical attention immediately. Symptoms of overdose may include gastrointestinal symptoms (nausea, vomiting, stomach pain), cardiovascular effects (elevated blood pressure), and renal effects. Etoricoxib cannot be removed by dialysis due to its high protein binding. There is no specific antidote; treatment is supportive and symptomatic.
What Are the Side Effects of Etoricoxib Brown?
Like all medicines, Etoricoxib Brown can cause side effects, although not everyone experiences them. The side effect profile of Etoricoxib Brown is identical to that of the originator product Arcoxia, as both contain the same active ingredient etoricoxib. Many side effects are dose-dependent, meaning they are less likely or less severe at the 30 mg dose compared to higher doses. It is important to recognize the warning signs that require immediate medical attention.
- Shortness of breath, chest pain, or swelling of the legs or feet (cardiovascular or heart failure signs)
- Sudden weakness or numbness on one side of the body, difficulty speaking, or sudden severe headache (signs of stroke)
- Yellowing of the skin or eyes (jaundice)—signs of liver damage
- Severe or persistent abdominal pain, or black (tarry) stools—signs of gastrointestinal bleeding
- Allergic reaction including skin ulcers or blisters, swelling of the face, lips, tongue, or throat causing difficulty breathing or swallowing
Very Common
May affect more than 1 in 10 people
- Stomach pain (abdominal pain)
Common
May affect up to 1 in 10 people
- Dry socket (post-extraction inflammation after dental surgery)
- Swelling of legs/feet due to fluid retention (peripheral edema)
- Dizziness, headache
- Palpitations, arrhythmia (irregular heartbeat)
- Elevated blood pressure (hypertension)
- Wheezing or shortness of breath (bronchospasm)
- Constipation, bloating, gastritis, heartburn, diarrhea, dyspepsia, nausea, vomiting
- Esophageal inflammation (esophagitis), mouth ulcers
- Altered liver function tests (elevated transaminases)
- Bruising (ecchymosis)
- Weakness, fatigue, flu-like symptoms
Uncommon
May affect up to 1 in 100 people
- Gastroenteritis, upper respiratory infection, urinary tract infection
- Changes in blood counts (decreased red cells, white cells, or platelets)
- Hypersensitivity reactions (including severe urticaria)
- Appetite changes, weight gain
- Anxiety, depression, reduced mental sharpness, hallucinations
- Taste changes, insomnia, numbness or tingling (paresthesia), drowsiness
- Blurred vision, eye irritation (conjunctivitis)
- Tinnitus (ringing in ears), vertigo
- Atrial fibrillation, rapid heart rate (tachycardia), heart failure, angina, myocardial infarction
- Flushing, stroke, transient ischemic attack, severe blood pressure elevation, vasculitis
- Cough, nosebleed (epistaxis)
- Dry mouth, gastric or duodenal ulcer, pancreatitis, irritable bowel syndrome
- Facial swelling, skin rash, itching (pruritus), redness (erythema)
- Muscle cramps, muscle pain/stiffness (myalgia)
- Elevated potassium (hyperkalemia), altered kidney function, proteinuria
- Chest pain
Rare
May affect up to 1 in 1,000 people
- Angioedema or anaphylaxis (life-threatening allergic reactions)
- Confusion, restlessness
- Hepatitis (liver inflammation)
- Low blood sodium (hyponatremia)
- Liver failure, jaundice
- Severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis)
Cardiovascular Risk
All NSAIDs, including selective COX-2 inhibitors, carry warnings about potential cardiovascular risks. The MEDAL (Multinational Etoricoxib and Diclofenac Arthritis Long-term) study, the largest NSAID outcome study ever conducted, compared etoricoxib with diclofenac in over 34,700 patients over a mean treatment period of 18 months and found comparable rates of thrombotic cardiovascular events between the two drugs. The European Medicines Agency (EMA) has concluded that the cardiovascular risk of etoricoxib is comparable to that of other NSAIDs within approved dose ranges.
Nevertheless, the risk may increase with dose and duration of use, which is why treatment should always employ the lowest effective dose for the shortest necessary period. Etoricoxib Brown 30 mg represents the lowest available dose and is therefore associated with the lowest dose-related cardiovascular risk among etoricoxib formulations. Patients with cardiovascular risk factors should have these risks discussed and regularly reassessed by their prescribing physician.
Blood Pressure Effects
Etoricoxib can raise blood pressure in a dose-dependent manner. In the MEDAL program, a higher proportion of patients on etoricoxib discontinued treatment due to hypertension-related adverse events compared to diclofenac. The blood pressure effect is most pronounced at higher doses (90 mg and 120 mg) and is generally modest at the 30 mg dose used for osteoarthritis. Nevertheless, blood pressure should be monitored within two weeks of starting treatment and periodically thereafter. If blood pressure rises significantly, your doctor may need to adjust your treatment, add or modify antihypertensive therapy, or discontinue etoricoxib.
If you experience any side effects, including those not listed here, report them to your healthcare provider. You can also report suspected side effects to your national pharmacovigilance authority (e.g., the Yellow Card Scheme in the UK, or the EMA EudraVigilance system in Europe). Reporting side effects helps monitor the ongoing safety of medicines and contributes to the collective knowledge about drug safety profiles.
How Should You Store Etoricoxib Brown?
Proper storage ensures that Etoricoxib Brown remains effective and safe throughout its shelf life. Follow these guidelines to maintain the quality of your medication:
- Keep out of the reach and sight of children – Accidental ingestion by children is a medical emergency. Store the medicine in a secure location that children cannot access.
- Store below 25°C (77°F) – Keep at room temperature, away from direct sunlight and heat sources. Do not refrigerate or freeze the tablets.
- Check the expiration date – Do not use Etoricoxib Brown after the expiry date (EXP) printed on the carton and blister strip. The expiration date refers to the last day of the indicated month.
- Keep in original packaging – Store the tablets in the original blister pack or bottle to protect from moisture and light. If the product comes in a bottle, keep it tightly closed. Do not transfer tablets to another container.
- Moisture protection – Etoricoxib tablets are moisture-sensitive. If the product contains a desiccant sachet, do not remove it from the bottle and do not swallow it.
- Proper disposal – Do not discard unused or expired tablets in household waste or flush them down the drain. Return unused tablets to a pharmacy for safe disposal through a medication take-back program. This helps protect the environment and prevents accidental exposure.
If you notice any visible changes to the tablets, such as discoloration, unusual odor, or crumbling, do not take them and consult your pharmacist. These changes may indicate degradation that could affect the safety or efficacy of the medicine.
What Does Etoricoxib Brown Contain?
Active Ingredient
Each film-coated tablet of Etoricoxib Brown contains 30 mg of etoricoxib as the active ingredient. Etoricoxib is a selective cyclo-oxygenase-2 (COX-2) inhibitor with the chemical name 5-chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]-2,3'-bipyridine. It is a white to off-white powder that is practically insoluble in water but freely soluble in organic solvents.
Inactive Ingredients (Excipients)
The inactive ingredients in Etoricoxib Brown serve to give the tablet its shape, stability, and protective coating. Typical excipients in etoricoxib film-coated tablets include:
- Tablet core: Calcium hydrogen phosphate (anhydrous), croscarmellose sodium (disintegrant), magnesium stearate (lubricant), microcrystalline cellulose (filler/binder). These excipients are widely used in pharmaceutical manufacturing and are generally well tolerated.
- Film coating: Hypromellose (film-forming agent), titanium dioxide E171 (opacifier/colorant), triacetin (plasticizer), and may contain additional colorants depending on the specific formulation. The film coating protects the tablet from moisture and makes it easier to swallow.
Some etoricoxib formulations contain lactose monohydrate as an excipient. If you have been told by your doctor that you have an intolerance to certain sugars, including lactose, consult your doctor or pharmacist before taking Etoricoxib Brown. Always check the patient information leaflet included with your specific product for the complete list of excipients. The sodium content is typically less than 1 mmol (23 mg) per tablet, meaning the product is essentially sodium-free.
Appearance and Packaging
Etoricoxib Brown 30 mg tablets are film-coated tablets. The specific color, shape, and markings may vary depending on the manufacturer and batch. The tablets are typically supplied in blister packs or bottles of various sizes. Not all pack sizes may be marketed in all countries. Always verify that you have received the correct medicine by checking the name, strength, and batch number on the packaging against your prescription.
Frequently Asked Questions About Etoricoxib Brown
Etoricoxib Brown is a generic selective COX-2 inhibitor containing etoricoxib. It is primarily used to treat pain and inflammation in osteoarthritis at a dose of 30 mg once daily. Etoricoxib is also approved for rheumatoid arthritis, ankylosing spondylitis, acute gouty arthritis, and short-term pain after dental surgery, though these indications typically require higher doses available from other formulations. It requires a prescription and is taken once daily.
Yes, Etoricoxib Brown contains the same active ingredient (etoricoxib) as the brand-name product Arcoxia. Generic medications undergo rigorous regulatory review to demonstrate bioequivalence, meaning they deliver the same amount of active ingredient into the bloodstream at the same rate as the originator. Etoricoxib Brown 30 mg is therapeutically equivalent to Arcoxia 30 mg with the same efficacy and safety profile.
Etoricoxib Brown selectively blocks the COX-2 enzyme involved in inflammation while largely sparing COX-1, which protects the stomach lining. Traditional NSAIDs like ibuprofen and naproxen block both COX-1 and COX-2, which may lead to more gastrointestinal side effects such as stomach ulcers and bleeding. Etoricoxib also has a long half-life of about 22 hours, allowing once-daily dosing, compared to two to four times daily for ibuprofen. However, selective COX-2 inhibitors require careful cardiovascular risk assessment before use.
Etoricoxib Brown can be taken with blood pressure medications, but it may reduce their effectiveness. ACE inhibitors, ARBs, and diuretics may become less effective due to etoricoxib's effects on sodium retention. Etoricoxib can also raise blood pressure, though this is less pronounced at the 30 mg dose. Your doctor should monitor blood pressure within two weeks of starting treatment and regularly thereafter. Adequate hydration is important to reduce the risk of kidney problems.
The most common side effect is stomach pain (very common, more than 1 in 10). Common side effects include headache, dizziness, palpitations, elevated blood pressure, gastrointestinal symptoms (heartburn, nausea, diarrhea, constipation, bloating), swelling of legs/feet due to fluid retention, bruising, fatigue, and flu-like symptoms. Most are mild to moderate and may be less frequent at the 30 mg dose compared to higher doses.
No, etoricoxib is not FDA-approved and is not available in the United States. The FDA declined approval in 2007, citing cardiovascular safety concerns relative to existing alternatives. However, etoricoxib is approved in over 80 countries, including throughout Europe (EMA-authorized), Latin America, and Asia-Pacific. Patients in the United States may be prescribed alternative COX-2 inhibitors such as celecoxib.
References
All information is based on current international medical guidelines, regulatory documents, and peer-reviewed research. No commercial funding was involved in the preparation of this article.
- Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the MEDAL programme. The Lancet. 2006;368(9549):1771–1781. doi:10.1016/S0140-6736(06)69666-9
- European Medicines Agency (EMA). Etoricoxib – Summary of Product Characteristics. Available at: www.ema.europa.eu
- Coxib and traditional NSAID Trialists' (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. The Lancet. 2013;382(9894):769–779. doi:10.1016/S0140-6736(13)60900-9
- National Institute for Health and Care Excellence (NICE). NSAIDs – prescribing issues. Clinical Knowledge Summary. 2024. Available at: cks.nice.org.uk
- British National Formulary (BNF). Etoricoxib Monograph. Available at: bnf.nice.org.uk
- Dougados M, van der Heijde D, Chen YC, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med. 2002;347(26):2104–2110.
- Laine L, Curtis SP, Cryer B, et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the MEDAL programme. The Lancet. 2007;369(9560):465–473.
- Rubin BR, Burton R, Navarra S, et al. Efficacy and safety profile of etoricoxib 120 mg compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum. 2004;50(2):598–606.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. 2023. Available at: www.who.int
- McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011;8(9):e1001098.
Medical Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, consisting of licensed physicians, pharmacists, and medical researchers with expertise in clinical pharmacology, rheumatology, and pain management. All content follows the GRADE evidence framework and adheres to international medical guidelines from EMA, WHO, NICE, and EULAR.
All medical claims are supported by Level 1A evidence from systematic reviews, meta-analyses of randomized controlled trials, and current clinical guidelines. Key sources include the MEDAL programme, CNT Collaboration meta-analysis, EMA product information, BNF monograph, and NICE clinical knowledge summaries.
iMedic receives no commercial funding from pharmaceutical companies. Our editorial content is entirely independent, with no advertising, sponsorship, or conflicts of interest. All content is reviewed according to our rigorous editorial standards.